MetabolismNews.net

Metabolism Xagena

Phase 2b TULIP study results with CETP inhibitor, TA-8995, a drug in the field of dyslipidemia, were published in the Lancet. The peer-reviewed article is entitled Cholesterol ester transfer protein i ...


Results from ETC-1002-009, a phase 2b study evaluating the efficacy and safety of ETC-1002 ( Bempedoic acid ) compared with placebo in patients with hypercholesterolemia on stable statin therapy, were ...


Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein cholesterol ( LDL ...


A study has compared the efficacy [ low-density lipoprotein cholesterol ( LDL-C ) lowering ] and safety of Alirocumab ( Praluent ), a fully human monoclonal antibody to proprotein convertase subtilisi ...


The objective of a study was to evaluate the efficacy and safety of extended dosing with Mipomersen ( Kynamro ) in patients with familial hypercholesterolaemia taking maximally tolerated lipid-lowerin ...


One-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the phase 2 ( OSLER-1 ) and phase 3 ( OSLER-2 ) open-label extension studies of Evolocumab ( Repatha ), a ...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published in The New Engla ...


Type 2 diabetes and obesity impair kidney function. Researchers have examined their respective contributions to urinary albumin excretion ( UAE ) and glomerular filtration rate ( GFR ) in patients wit ...


The purpose was to study whether mortality and cardiovascular morbidity differ in non-invasive ventilation (NIV)-treated patients with severe obesity-hypoventilation syndrome ( OHS ) as compared with ...


Metabolic surgery is a novel therapy for mild obesity ( BMI 30-35 Kg/m2 ) in type 2 diabetes mellitus ( T2DM ) patients. The ABCD score, which comprise age, BMI, C-peptide level, and duration of type ...


It is unclear whether an intensive program of weight loss combined with exercise prevents the onset of knee pain among those at high risk. Researchers have examined whether an intensive lifestyle in ...


Statins are the treatment of choice for dyslipidemia, primarily lowering elevated LDL-C levels and reducing the occurrence of major cardiovascular events. In June 2011, the FDA ( Food and Drug Admin ...


Adding the drug Ezetimibe to treatment with Simvastatin lowers the risk of future cardiovascular problems, including myocardial infarction and stroke, in high-risk patients with acute coronary syndrom ...


The FDA ( Food and Drug Administration ) has approved the New Drug Application ( NDA ) for Saxenda ( Liraglutide 3 mg ), the first once-daily human glucagon-like peptide-1 ( GLP-1 ) analogue for the t ...


It is unclear whether high-density lipoprotein ( HDL ) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of ...


The European Medicines Agency ( EMA ) has recommended granting a marketing authorisation for Mysimba ( Naltrexone / Bupropion ) for weight management of overweight or obese adults. The medicine is rec ...


Data, published in The Lancet, from two phase 3 studies, RUTHERFORD-2 and TESLA with Evolocumab, a novel investigational low-density lipoprotein cholesterol ( LDL-C )-lowering medication, resulted in ...


Results from four Phase 3 ODYSSEY trials of Alirocumab in people with hypercholesterolemia. Alirocumab is an investigational monoclonal antibody targeting PCSK9 ( proprotein convertase subtilisin / k ...


By inhibiting apolipoprotein B ( ApoB ) synthesis, Mipomersen ( Kynamro ) can significantly reduce ApoB-containing lipoproteins in hypercholesterolemic patients. The purpose of a study was to ascer ...


Homozygous familial hypercholesterolaemia ( HoFH ) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol ( LDL-C ) and accel ...


A meta-analysis of individual participant data of eight prospective cohort studies from Europe and the US has investigated the association between serum 25-hydroxyvitamin D concentrations [ 25(OH)D ] ...


Thirty-six percent of adults in the United States are obese, and many cannot lose sufficient weight to improve health with lifestyle interventions alone. Researches have conducted a systematic revi ...


National and international guidelines recommend fasting lipid panel measurement for risk stratification of patients for prevention of cardiovascular events. Yet, the prognostic value of fasting versus ...


Vitamin-D insufficiency is associated with many disorders, leading to calls for widespread supplementation. Some investigators suggest that more clinical trials to test the effect of Vitamin-D on diso ...


In short-term randomized trials ( duration, 1 to 2 years ), bariatric surgery has been associated with improvement in type 2 diabetes mellitus. Researchers have assessed outcomes 3 years after the ...


Efficacy and safety of Alirocumab were compared with Ezetimibe ( Ezetrol, Zetia ) in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy ...


Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced pla ...


Findings from recent meta-analyses of Vitamin D supplementation without co-administration of Calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, ...


Amgen has announced that the Phase 3 RUTHERFORD-2 ( RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder Study-2 ) trial evaluating Evolocumab in combination ...


Current osteoporosis medications increase bone mineral density ( BMD ) modestly and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering anabolic agents and bisph ...


Findings from recent meta-analyses of Vitamin D supplementation without co-administration of calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, ...


The results from a phase 2 trial evaluating Romosozumab in postmenopausal women with low bone mineral density ( BMD ) were published in the New England Journal of Medicine ( NEJM ).The trial demonstra ...


Rhizomelic chondrodysplasia punctata ( RCDP ) is a rare disorder of peroxisomal metabolism, with an estimated incidence of 1:100.000. There are 3 genetic subtypes. RCDP type 1, caused by mutations in ...


Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. A study has assessed the efficacy and safety of the microsomal triglyceride transfer protein ( MTP ) inh ...


Enteral nutrition is recommended for patients in the intensive-care unit ( ICU ), but it does not consistently achieve nutritional goals.Researchers have assessed whether delivery of 100% of the energ ...


Statins are commonly prescribed for management of dyslipidaemia and cardiovascular disease. Increased fitness is also associated with low mortality and is recommended as an essential part of promoting ...


Osteoporosis medications increase bone-mineral density ( BMD ) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy.Researchers ...


Low levels of total 25-Hydroxyvitamin D are common among black Americans. Vitamin D-binding protein ( DBP ) has not been considered in the assessment of vitamin D deficiency.In the Healthy Aging in Ne ...


Arena Pharmaceuticals has officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it wishes to withdraw its application for a marketing authorisation for Belviq, a medicin ...


The risks of developing kidney failure and a calcium deficiency from osteoporosis drug Zoledronic acid ( Aclasta; Reclast ) are extremely rare, according to researchers at Loyola University Health Sys ...


On 13 December 2012, the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Kynam ...


On 18 October 2012, the Committee for Medicinal Products for Human Use ( CHMP ) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Qsiva, int ...


New data have shown that Forteo ( Teriparatide; Forsteo ) significantly increased lumbar spine volumetric bone mineral density ( vBMD ) compared to Risedronate ( Actonel ) in men with glucocorticoid-i ...


Results from a prospective study have shown that patients with a body mass index ( BMI ) in the obese range live on average two to three months less after a pancreatic cancer diagnosis, compared with ...


Sanofi and Regeneron Pharmaceuticals have announced that the Phase 3 ODYSSEY MONO trial with Alirocumab, an investigational monoclonal antibody targeting PCSK9 ( proprotein convertase subtilisin/kexin ...


Merck ( MSD ) has announced that the HPS2-THRIVE ( Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events ) study of Tredaptive ( extended-release Niacin / Laropiprant ) ...


Two clinical studies were conducted to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential immunogenicity of single and multiple escalating doses ( IV [ intravenous ] an ...


The results from a phase II trial for Odanacatib, a cathepsin K ( cat-K ) inhibitor in development for the treatment of osteoporosis in post-menopausal women, were presented at the 34th Annual Meeting ...


La Food and Drug Administration ( FDA ) has approved a new indication for Prolia ( Denosumab ) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia, the firs ...


The emerging idea that obesity may have an infectious origin gets new support in a cross-sectional study by University of California San Diego School of Medicine researchers who found that children ex ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati